Optional copayments on anti-cancer drugs

BMJ (Online)

Volumn 346, Issue 7893, 2013, Pages

  Van De Vooren, Katelijne ^a   Curto, Alessandro ^a   Garattini, Livio ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; WART VIRUS VACCINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH SERVICE; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; REIMBURSEMENT; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COST CONTROL; COST-BENEFIT ANALYSIS; DEDUCTIBLES AND COINSURANCE; HEALTH CARE COSTS; HUMANS; NEOPLASMS; PATIENT PARTICIPATION;

EID: 84873341959     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f349     Document Type: Article

References (21)

1. Walsh G. Biopharmaceutical benchmarks 2010. Nature Biotech 2010;28:917-24.
2. NICE. Appraising life extending, end of life treatments. 2008. www.nice.org.uk/media/88A/F2/SupplementaryAdviceTACEo.L.
3. Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, et al. Delivering affordable care in high-income countries. Lancet Oncol 2011;12:933-80.
4. Garattini L, van de Vooren K, Zaniboni A. Ethics for end-of-life treatments: metastatic colorectal cancer is one example. Health Policy 2013;109:97-103.
5. Tappenden P, Jones R, Paisley S, Carroll C. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol. Assess 2007;11:1-128, iii-iv.
6. NICE. Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after firstline chemotherapy. NICE technology appraisal guidance 2012. www.nice. org.uk/nicemedia/live/13651/57924/57924.pdf.
7. Richards M. A report for the secretary of state for health. Improving access to medicines for NHS patients. 2008. www.dh.gov.uk/dr-consum-dh/groups/ dh-digitalassets/@dh/@ en/documents/digitalasset/dh-089952.pdf
8. Raftery J. NICE and the challenge of cancer drugs. BMJ 2009;338:-b67.
9. Garattini L, van de Vooren K. HPV vaccination for boys Talking economic sense. J Sex Med 2012 Jul 3 [Epub ahead of print].
10. Garattini L, van de Vooren K. Extending HPV vaccination to boys: an economic perspective. [Electronic response to Castle P, Should HPV vaccine be given to men] BMJ 2012 Jan 13. www.bmj.com/rapid-response/2012/01/13/re-should- hpv-vaccine-be-given-men.
11. De Souza J, Polite B, Manning W, Fendrick A, Ratain M. Value-based insurance design in oncology. Lancet Oncol 2011;12:321-3.
12. Drummond M, Towse A. Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe Eur J Health Econ 2012;13:1-5.
13. Gemmill M, Thomson S, Mossialos E. What impact do prescription drug charges have on efficiency and equity Evidence from high-income countries. Int J Equity Health 2008;2:12.
14. Trivedi A, Moloo H, Mor V. Increased ambulatory care copayments and hospitalizations among the elderly. N Engl J Med 2010;362:320-8.
15. Freemantle N, Bloor K. Lessons from international experience in controlling pharmaceutical expenditure I: Influencing patients. BMJ 1996;312:1469-71. (Pubitemid 26000750)
16. Garattini L, van de Vooren K. Could co-payments on drugs help to make EU health care systems less open to political influence Eur J Health Econ 2012 Sep 9. [Epub ahead of print.]
17. Giuliani G, Selke G, Garattini L. The German experience in reference pricing. Health Policy 1998;44:73-85. (Pubitemid 28238254)
18. Garattini L, Ghislandi S. Off-patent drugs in Italy. A short-sighted view Eur J Health Econ 2006;7:79-83. (Pubitemid 43375576)
19. Galizzi M, Ghislandi S, Miraldo M. Effects of reference pricing in pharmaceutical markets: a review. Pharmacoeconomics 2011;29:17-33.
20. Drummond M, Jonsson B, Rutten F, Stargardt T. Reimbursement of pharmaceuticals: reference pricing versus health technology assessment. Eur J Health Econ 2011;12:263-71.
21. Stargardt T. The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany. Eur J Health Econ 2010;11:267-77.